LY3650150 Clinical Trials
2 recruitingDrug
Phase 32
Showing 1–2 of 2 trials
Recruiting
Phase 3
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
Perennial Allergic Rhinitis (PAR)
Eli Lilly and Company450 enrolled77 locationsNCT06339008
Recruiting
Phase 3
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Eli Lilly and Company510 enrolled194 locationsNCT06338995